Recently, MedComm - Future Medicine (ISSN: 2769-6456), published by Wiley, the world's leading publisher, was launched online. MedComm - Future Medicine carries on the founding spirit and mission of Signal Transduction and Targeted Therapy (2020 IF 18.187) and MedComm o continue to bring insightful, valuable, and impactful high-quality papers. The journal is now open for submission and expected to publish papers continuously in April.

MedComm - Future Medicine focuses on the discovery of new mechanisms of disease, the application of new cutting-edge technologies in related fields, and the proposal of new interventions for disease to address medical challenges. Relevant topics include, but not limited to, the development of breakthrough technologies and treatments, interdisciplinary approaches, the use of big data and artificial intelligence in healthcare delivery, the use of precision medicine for early detection and outcome prediction of major diseases, gene therapy, stem cell and regenerative medicine, and new drug development and clinical research.

Its editorial board is composed of renowned scientists from around the world, gathering a number of academicians from home and abroad, including several members of UK Academy of Medical Sciences, the American Academy of Sciences, and highly cited scholars, with more than 50% being top foreign scholars. The editors-in-chief include Prof. Robin Ali from King's College London, Prof. Michael Karin from the University of California, and Prof. Kang Zhang from Macau University of Science and Technology.

Prof. Robin Ali, a member of the UK Academy of Medical Sciences, has published many articles in top international journals such as Nature, Cell, New Engl J Med, Nat Biotechnol, Nat Med, etc., with a personal h-index of 75 and over 20,000 citations. Prof. Michael Karin, a member of the American Academy of Sciences, a member of the American Academy of Medical Sciences, and a member of the American Academy of Arts and Sciences, has published many highly cited articles in top international journals such as Cell, Nature, Science, Nat Med, Cancer Cell, etc., with a personal h-index of 269 and over 300,000 citations. Prof. Kang Zhang, a global highly cited scholar for cross disciplinary  for many years, a co-editor-in-chief of Signal Transduction and Targeted Therapy, has published many high-impact articles in top international journals such as Cell, Nature, Science, New Engl J Med, Nat Med, PNAS, etc., with a personal h-index up to 90 and over 50,000 citations.

MedComm - Future Medicine is a peer-reviewed, open-access journal that aims to break through the limitations of current medical treatment and change the paradigm of future treatment by publishing high-quality research in the fields of medicine, biology and related interdisciplines, covering the latest advances in biomedical research and healthcare, including innovations in medical screening, diagnosis, prevention and treatment technologies, research into new mechanisms of disease pathogenesis, and the development of new interventions with clinical translation potential.

Article publication charges are waived for the period 2022-2023 and the journal focuses on advances that will have a significant impact on human health care, with rapid publication of important research results.  Areas covered include multi-omics, bioinformatics, medical artificial intelligence, stem cell and regenerative medicine, gene editing and therapeutics; the human health and diseases covered include, but not limited to, cancer, cardiovascular disease, autoimmune disease, neurological disorders, health maintenance, and delayed aging.

MedComm - Future Medicine cordially invites all to submit manuscripts.

Profile of editors-in-chief

Robin Ali

Robin Ali is Professor of Human Molecular Genetics at King’s College London and Director of The KCL Centre for Cell and Gene Therapy. He is also Deputy Director, NIHR Guy’s and St Thomas’ Biomedical Research Centre and Director of the KCL/BRC Advanced Therapies Accelerator. He has published over 200 peer-reviewed papers including landmark papers and preclinical therapeutic proof-of-concept (POC) studies for many different ocular disorders. Prof. Ali has received numerous prizes and awards for his work, including the Pfizer/ARVO Translational Award for Ophthalmology (2010) and the Alcon Research Institute Award (2009). In 2007 he was elected to the Academy of Medical Sciences as its youngest elected member and in 2009 elected NIHR Senior Investigator (re-elected in 2014). He is past President of the European Society of Gene and Cell Therapy and has served on the advisory boards of a number of funding bodies.

Michael Karin

Michael Karin, is currently a Distinguished Professor of Pharmacology and Pathology at the University of California San Diego School of Medicine. Dr. Karin was elected as a member of the US National Academy of Sciences in 2005, the National Academy of Medicine in 2011. He became a fellow of the American Association for Cancer Research Academy in 2017. Dr. Karin’s current activity primarily focuses on understanding the relationship between inflammation, cancer, and metabolic disease as well as the signaling mechanisms used by receptors involved in inflammation and innate immunity. He has published over 300 papers in the international top journals (including over 100 Nature, Science and Cell articles) and has a citation over 300, 000 and h-index of 269.

Kang Zhang

Kang Zhang, MD, PhD is a Chair Professor of the Faculty of Medicine, Macau University of Science and Technology (MUST). Among his honors include AAAS fellow, fellow of American Institute for Medical and Biological Engineering, memberships in Association of American Physicians and American Society of Clinical Investigation; Burroughs Wellcome Clinical Scientist Award in Translational Research; the Ophthalmologist 100 Powerlist, global highly cited researcher in cross-field. Prof. Zhang has published over 200 peer-reviewed manuscripts in top peer-reviewed journals covering a wide range of topics in genetics, epigenetics, stem cells, nano-engineering and 3D printing, clinical trials, and artificial intelligence. He has more than 50,000 citations and an h-index of 90.

MedComm - Future Medicine 

Editor(s)-in-Chief

Robin Ali, King’s College London

Michael Karin, University of California San Diego

Kang Zhang, Macau University of Science and Technology

Associate Editors 

Jayakrishna Ambati, University of Virginia

Stephan Beck, University College London

Heping Cheng, Peking University

Kanmin Xue, University of Oxford

Assistant Editors

Daniel Baptista Hon, Macau University of Science and Technology

Yuanxu Gao, Macau University of Science and Technology

Ting Li, Macau University of Science and Technology

Jun Zou, West China Hospital of Sichuan University

Editorial Board 

Takahisa Furukawa, Osaka University

Fan Fan Hou, Southern Medical University

Wei Li, National Institute of Health

Tianming Liu, University of Georgia

Yang Shi, University of Oxford

Periasamy Sundaresan, Aravind Medical Research Foundation

Woong Sun, Korea University

Yang Sun, Stanford University

Frank Talke, University of California San Diego

Zhongzhao Teng, University of Cambridge

Andrew Teschendorff, University of Cambridge

Stephen Tsang, Columbia University

Shan X. Wang, Stanford University

David Williams, University of California Los Angeles

Peng Xiang, Sun Yat-Sen University

Wenjun Xiong, City University of Hong Kong

Zhenglin Yang, Sichuan Provincial People's Hospital

Xianjie Yang, University of California Los Angeles

Liangfang Zhang, University of California San Diego

Jiankang Zhu, Southern University of Science and Technology

Homepage of the journal:

https://onlinelibrary.wiley.com/journal/27696456

Submission website:

https://mc.manuscriptcentral.com/medcomm-futmed